Andrew J. Wroe, PhD

To evaluate patient-specific quality assurance (PSQA) measurements across 18 disease sites treated with intensity modulated proton therapy (IMPT) from January 2024 through August 2025.

Recent Phase 3 trial literature provides evidence for IMPT as the standard-of-care treatment for oropharyngeal cancer. Proton dynamic arc therapy (DynamicArc) potentially offers further refinement of IMPT. The goal of this work was to compare DynamicArc versu...